about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionMetMaxStruct: A Tversky-Similarity-Based Strategy for Analysing the (Sub)Structural Similarities of Drugs and Endogenous MetabolitesBuilding a virtual ligand screening pipeline using free software: a surveyAmygdala-dependent fear is regulated by Oprl1 in mice and humans with PTSD.Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening.The essential roles of chemistry in high-throughput screening triageChallenges and opportunities in the advancement of nanomedicines.Phenotypic screens targeting neurodegenerative diseases.Chemical predictive modelling to improve compound quality.What does the aromatic ring number mean for drug design?Innovative computer-aided methods for the discovery of new kinase ligands.Multivalent Inhibitors of Channel-Forming Bacterial Toxins.Understanding the foundations of the structural similarities between marketed drugs and endogenous human metabolitesSynthesis, antiviral activity and structure-activity relationship of 1-(1-aryl-4,5-dihydro-1H-imidazoline)-3-chlorosulfonylureas and products of their cyclization.A 'rule of 0.5' for the metabolite-likeness of approved pharmaceutical drugs.Acetylcholinesterase reactivators (HI-6, obidoxime, trimedoxime, K027, K075, K127, K203, K282): structural evaluation of human serum albumin binding and absorption kinetics.Direct synthesis of imino-C-nucleoside analogues and other biologically active iminosugars.Potential of agricultural fungicides for antifungal drug discovery.De novo Drug Design - Ye olde Scoring Problem Revisited.
P2860
Q24273350-664380E2-BDC5-42BA-ACA9-D6CD937ACFB5Q28597594-208788BA-7D6C-4EFA-B05E-E517D081FBB4Q30044592-32E2BE43-4517-492C-9140-1BFDF3F3BF65Q30437236-8DFDB015-84A0-4082-B1AC-B9E163FF1D2CQ31139520-2EDA5099-B8B8-4C09-8B60-F421C6B512CFQ34435458-DC034A86-EFED-4944-A540-C03FEB6198C4Q36417295-B327F4F1-F605-4B0F-A222-EBF07B4709EDQ38130052-D1D9157A-2B92-474C-A96E-EBA8C04D5FDBQ38167262-47C2BCFB-94AC-4ED0-B983-2C5185FEA88BQ38222473-135017C8-82FD-4321-AFFB-8B658BE6A2C6Q38814898-B28C3E62-F351-446B-BC4C-35D4B957304CQ38911726-F10E7975-3DAE-49EF-8D3C-67280E3F569FQ40605856-A6DAF27B-4605-4262-9EEA-9BDF7E6C34A6Q41089151-9820DF03-C11C-47CF-83EF-DF855C6EC9B7Q41861993-C0E8B0D1-B70A-48EA-AE4A-7EA30873B650Q42580614-D2E2F63E-BD73-4D1A-B413-8C1F6543E578Q43066871-39201E42-40C1-4F99-AD20-99B3F96AB3C6Q46642109-6DEF79D4-D5EB-476F-B5A5-8933C82C5428Q51028429-03E56C6B-57A1-4B7E-8E6C-7A3BB796AAA9
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Going further than Lipinski's rule in drug design.
@en
Going further than Lipinski's rule in drug design.
@nl
type
label
Going further than Lipinski's rule in drug design.
@en
Going further than Lipinski's rule in drug design.
@nl
prefLabel
Going further than Lipinski's rule in drug design.
@en
Going further than Lipinski's rule in drug design.
@nl
P2860
P1476
Going further than Lipinski's rule in drug design.
@en
P2093
W Patrick Walters
P2860
P304
P356
10.1517/17460441.2012.648612
P407
P577
2012-01-13T00:00:00Z